Cargando…

An Oral Contraceptive Containing Estetrol 15 MG and Drospirenone 3 MG Has Limited Effects on Endocrine and Metabolic Parameters

Background: Most combined oral contraceptives (COCs) contain ethinylestradiol (EE), an estrogen component known to increase the risk of venous thromboembolic events. Previous phase 2 trials have shown that Estetrol (E4), a naturally-occurring estrogen produced by the human fetal liver, in combinatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klipping, Christine, Duijkers, Ingrid J M, Jost, Maud, Bastidas, Adriana, Foidart, Jean Michel F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Reproductive Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090764/ http://dx.doi.org/10.1210/jendso/bvab048.1482

Ejemplares similares

The Effect of Estetrol/Drospirenone on Ovarian Function Is Similar to a Well-Established Combined Oral Contraceptive: Results From a Phase 2 Study
por: Duijkers, Ingrid J M, et al.
Publicado: (2021)

Low Thrombin Generation in Users of a Contraceptive Containing Estetrol and Drospirenone
por: Morimont, Laure, et al.
Publicado: (2022)

The benefits of estetrol addition to drospirenone for contraception
por: Foidart, Jean Michel, et al.
Publicado: (2023)

Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: Results of a phase II dose-finding pilot study
por: Duijkers, Ingrid J.M., et al.
Publicado: (2015)

Estetrol/Drospirenone: A Review in Oral Contraception
por: Lee, Arnold, et al.
Publicado: (2022)

Contraceptive efficacy and tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study
por: Klipping, Christine, et al.
Publicado: (2012)

Correction: Estetrol/Drospirenone: A Review in Oral Contraception
por: Lee, Arnold, et al.
Publicado: (2022)

Estetrol‐Drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia
por: Gemzell‐Danielsson, K, et al.
Publicado: (2021)

RF34 | PMON202 The Human Metabolic Profile of Estetrol
por: Gérard, Céline, et al.
Publicado: (2022)

Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives
por: Mawet, Marie, et al.
Publicado: (2015)

Long-term tolerability of ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study
por: Klipping, Christine, et al.
Publicado: (2012)

A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg
por: Palacios, Santiago, et al.
Publicado: (2019)

Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone
por: Römer, Thomas, et al.
Publicado: (2021)

Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime
por: Palacios, Santiago, et al.
Publicado: (2020)

Correction: Oral Progestins in Hormonal Contraception: Importance and Future Perspectives of a New Progestin Only-Pill Containing 4 mg Drospirenone
por: Römer, Thomas, et al.
Publicado: (2021)

Estetrol: A New Choice for Contraception
por: Fruzzetti, Franca, et al.
Publicado: (2021)

Evaluation of the food effect on a drospirenone only contraceptive containing 4 mg administered with and without high-fat breakfast in a randomised trial
por: Regidor, P.-A., et al.
Publicado: (2022)

Estetrol Combined to Progestogen for Menopause or Contraception Indication Is Neutral on Breast Cancer
por: Gallez, Anne, et al.
Publicado: (2021)

Effects of hormone therapy containing 2 mg drospirenone and 1 mg 17β-estradiol on postmenopausal exacerbation of Meniere's disease: Preliminary study
por: Grillo, Caterina Maria, et al.
Publicado: (2021)

Estetrol and Mammary Gland: Friends or Foes?
por: Gallez, Anne, et al.
Publicado: (2021)

Efficacy and safety of drospirenone 2 mg/17β-estradiol 1 mg hormone therapy in Korean postmenopausal women
por: Park, Bo Ra, et al.
Publicado: (2017)

Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database
por: Madigan, David, et al.
Publicado: (2018)

Estetrol: From Preclinical to Clinical Pharmacology and Advances in the Understanding of the Molecular Mechanism of Action
por: Gérard, Céline, et al.
Publicado: (2023)

SUN-LB001 Estetrol (E4) Is a Unique Estrogen with Selective Actions in Tissues Which Are Distinctly Different from the Actions of SERMs
por: Foidart, Jean-Michel, et al.
Publicado: (2019)

Efficacy and safety of an oral contraceptive containing ethinylestradiol 20 µg/drospirenone 3 mg (24/4 regimen) in three indications in the People’s Republic of China: a comparison with international studies
por: Marr, Joachim, et al.
Publicado: (2015)

Bleeding profile of women using a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg
por: Palacios, S., et al.
Publicado: (2020)

Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive: An Open-Label, Randomized, Crossover Study of Estradiol Valerate/Dienogest versus Ethinylestradiol/Levonorgestrel
por: Klipping, Christine, et al.
Publicado: (2012)

Drospirenone/ethinyl estradiol 3 mg/20 μg (24/4 day regimen): hormonal contraceptive choices – use of a fourth-generation progestin
por: Bachmann, Gloria, et al.
Publicado: (2009)

Estrogen receptors and estetrol-dependent neuroprotective actions: a pilot study
por: Tskitishvili, Ekaterine, et al.
Publicado: (2016)

FRI378 Estetrol Prolongs Anagen In Healthy Female Scalp Hair Follicles By Positively Modulating Dermal Papilla Functions And Generation Of Progenitor Stem Cells Ex Vivo
por: Gerard, Celine, et al.
Publicado: (2023)

Vitamin D serum levels in women using contraception containing drospirenone – a preliminary study
por: Ciebiera, Michał, et al.
Publicado: (2017)

A single-arm study to evaluate the transfer of drospirenone to breast milk after reaching steady state, following oral administration of 4 mg drospirenone in healthy lactating female volunteers
por: Melka, Dace, et al.
Publicado: (2020)

Mifepristone 5 mg versus 10 mg for emergency contraception: double-blind randomized clinical trial
por: Carbonell, Josep Lluis, et al.
Publicado: (2015)

A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms
por: Wichianpitaya, Jirath, et al.
Publicado: (2013)

Efficacy and safety of a 24-day regimen of drospirenone-containing combined oral contraceptive in Korean women
por: Kim, Nayoung, et al.
Publicado: (2015)

Investigation of the Hemostatic Effect of a Transdermal Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene Compared with a Monophasic Oral Contraceptive Containing 0.03 mg Ethinyl Estradiol and 0.15 mg Levonorgestrel: An Open-Label, Randomized, Crossover Study
por: Junge, Wolfgang, et al.
Publicado: (2013)

Contraceptive use and discontinuation among women aged 15–24 years in Kenya
por: Kungu, Wambui
Publicado: (2023)

The Efficacy of the Yasmin[Ethinylestradiol-Drospirenone (0.03/3 mg)] Treatment for Postoperative Abortion: A Protocol of Meta-Analysis
por: Tian, Tian, et al.
Publicado: (2022)

Preparation and Evaluation of Intravaginal Ring Containing Drospirenone
por: Zhang, Ying, et al.
Publicado: (2013)

A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety
por: Gaspard, Ulysse, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dfs0ufq23f00smi8k407nvrk4i